John Cochran Division, Department of Veteran Affairs Medical Center, St. Louis, MO 63106, United States.
Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63110, United States.
Bioorg Med Chem Lett. 2023 Jun 1;89:129301. doi: 10.1016/j.bmcl.2023.129301. Epub 2023 Apr 23.
An internal collection of commercial and synthetically derived small molecule compounds was screened against several drug-resistant bacterial pathogens. Compound 1, a known N, N-disubstituted 2-aminobenzothiazole, was found to be a potent inhibitor of Staphylococcus aureus and several associated clinically relevant strains of methicillin-resistant S. aureus suggesting a possible novel mechanism of inhibition. It failed to show activity in any of the Gram-negative pathogens it was tested in. Evaluation in Escherichia coli BW25113 and Pseudomonas aeruginosa PAO1, as well as in their respective hyperporinated and efflux pump-deletion mutants revealed that activity in Gram-negative bacteria is diminished because this benzothiazole scaffold is a substrate for bacterial efflux pumps. Several analogs of 1 were synthesized to generate basic structure-activity relationships for the scaffold which highlighted that the N-propyl imidazole moiety was critical for the observed antibacterial activity.
内部汇集了商业和合成小分子化合物,对几种耐药性细菌病原体进行了筛选。化合物 1 是一种已知的 N,N-二取代 2-氨基苯并噻唑,对金黄色葡萄球菌和几种相关的耐甲氧西林金黄色葡萄球菌临床相关株具有很强的抑制作用,提示可能存在一种新的抑制机制。它在测试的任何革兰氏阴性病原体中均没有显示出活性。在大肠杆菌 BW25113 和铜绿假单胞菌 PAO1 及其各自的超磷酸化和外排泵缺失突变体中的评估表明,革兰氏阴性菌中的活性降低,因为该苯并噻唑支架是细菌外排泵的底物。合成了 1 的几种类似物,以生成支架的基本结构-活性关系,这突出表明 N-丙基咪唑部分对于观察到的抗菌活性至关重要。